研究者業績
基本情報
- 所属
- 藤田医科大学 医療科学部/大学院医療科学研究科 研究推進ユニット レギュラトリーサイエンス分野 ユニット長, 分野教授(兼任)精神・神経病態解明センター 神経化学部門 部門長
- 学位
- 博士(医学)(名古屋大学大学院医学系研究科)
- J-GLOBAL ID
- 201001019721259872
- researchmap会員ID
- 6000026156
- 外部リンク
経歴
8-
2024年4月 - 現在
-
2022年4月 - 現在
-
2017年4月 - 2022年3月
-
2016年4月 - 2017年4月
-
2012年4月 - 2016年3月
学歴
3-
2003年4月 - 2007年3月
-
2001年4月 - 2003年3月
-
1997年4月 - 2001年3月
受賞
7-
2017年10月
-
2011年10月
-
2011年8月
論文
159-
Neuroscience 603 239-251 2026年5月25日Animal models are essential for studying aversive states such as fear and pain. Facial expressions may provide non-invasive readouts of aversive states in animals. This study investigated whether changes in facial expressions, which are potentially consistent between humans and mice, can serve as objective indicators of fear responses and distinguish fear from pain. We analyzed changes in the facial expressions of mice associated with conditioned fear stress (CFS) using convolutional neural networks (CNNs). Photographs of CFS and control mice were analyzed using four advanced CNN models: VGG16, ResNet50, DenseNet121, and InceptionV3. The CNNs identified CFS mice from facial images under contrasts: control/non-freezing vs CFS/freezing and control/non-freezing vs CFS/non-freezing, with consistently high performance (Control/non-freezing vs CFS/freezing: sensitivity 0.942, specificity 0.929, accuracy 0.935, precision 0.929, AUC 0.966; Control/non-freezing vs CFS/non-freezing: sensitivity 0.912, specificity 0.900, accuracy 0.906, precision 0.902, AUC 0.950). The ability to detect CFS without freezing decreased as stress intensity weakened, from an AUC of 0.950 to 0.701, suggesting that CNNs can detect facial changes depending on the degree of stress exposure. Facial changes were particularly pronounced in freezing mice, further supporting their association with CFS-related emotional responses. During testing, mice were returned to the conditioning chamber without shock; therefore, this facial expression could reflect fear response rather than pain response. These findings demonstrate the potential of CNNs to serve as non-invasive tools for detecting stress-induced affective changes in mice.
-
Neurochemistry international 197 106184-106184 2026年5月14日High salt (HS) intake is a major risk factor of hypertension and has been implicated in emotional and cognitive decline. On the other hand, dietary supplementation may represent a potential preventive strategy against health risks induced by HS intake. Soybean lecithin is widely used as a phospholipid supplement. Here, we investigated the effects of lysolecithin enriched in lysophosphatidylcholine (>70% of total phospholipids; LPC70) on hypertension and behavioral impairments under high-salt diet (HSD) conditions in mice. To further characterize these effects, we examined changes in prostaglandin (PG)-related pathways by integrating gene expression and lipidomic analyses. Mice were fed an HSD (chow containing 8% NaCl) with or without LPC70 for 10 weeks. HSD elevated systolic blood pressure and impaired social behavior and object recognition memory in mice. Quantitative gene expression analyses revealed that HSD increased renal expression of cyclooxygenase-2 (COX-2) and EP3 (PGE2 receptor), and reduced expression of DP1 (PGD2 receptor) in the prefrontal cortex. LPC70 attenuated these changes in behavior, blood pressure, and PG-related gene expression. Furthermore, lipidomic analyses revealed that HSD reduced circulating arachidonic acid (AA) levels, whereas LPC70 increased AA-derived PG, such as PGE2 and PGD2, in HSD-fed mice. These findings demonstrate that LPC70 may protect against hypertension and behavioral impairments under HSD conditions in mice, potentially in association with modulation of PG signaling. LPC70 may serve as a functional dietary component that reshapes lipid mediator signaling under HSD conditions.
-
Neurochemistry international 195 106141-106141 2026年5月Multiple sclerosis (MS) is a common autoimmune demyelinating disease of the central nervous system (CNS). Although activation of the kynurenine (KYN) pathway has been observed in patients with MS, its pathological significance remains unclear. In this study, we investigated the role of the KYN pathway in MS using an experimental autoimmune encephalomyelitis (EAE) mouse model, a widely recognized animal model of MS. We found an increase in the expression of kynureninase (KYNU), a key enzyme in the KYN pathway that is specifically localized within monocytes in the spinal cord of EAE mice. This was accompanied by a significant accumulation of quinolinic acid (QUIN) in the spinal cord. Importantly, similar increases in KYNU expression and QUIN levels were observed in the spinal cord of proteolipid protein overexpressing mice (PLP-tg mice), another model of demyelination. Notably, KYNU knockout (KO) reduced EAE severity and monocyte recruitment to the spinal cord of EAE model mice. These findings suggest that the increase in KYNU expression and the subsequent accumulation of QUIN may contribute to the exacerbation of MS. Taken together, our results indicate that KYNU could be a novel therapeutic target for MS.
-
Trials 27(1) 2026年3月13日BACKGROUND: Although the number of frozen-thawed blastocysts transfer is increasing worldwide, the live birth rate following blastocyst transfer using assisted reproductive technology remains at 30-60%. Thus, improving the pregnancy rate per transfer is an urgent issue. In a previous retrospective study, we evaluated the use of granulocyte-macrophage colony-stimulating factor (GM-CSF)-containing medium for recovery culture to improve the outcomes of frozen-thawed blastocyst transfers. The results demonstrated that the live birth rates increased by approximately 10% following recovery culture in the GM-CSF-containing culture medium. This study aims to prospectively evaluate whether GM-CSF-containing blastocyst recovery culture following thawing increases live birth. METHODS: This is a multicenter, randomized, parallel-group, active-controlled, single-blind trial. The recruitment target is 750 participants meeting the criteria. Enrolled patients are randomized 1:1 to the GM-CSF-containing culture medium group (test group) or the non-GM-CSF-containing culture medium group (control group). The blastocyst recovery culture after warming was defined as an intervention in this study; frozen-thawed blastocysts will be cultured for 3-7 h in GM-CSF-containing medium (test group) or medium without GM-CSF (control group) followed by blastocyst transfer. The primary outcome will be live birth. We will also evaluate embryo transfer outcomes as secondary efficacy endpoints and evaluate perinatal and neonatal outcomes as a safety endpoint. DISCUSSION: This is the first large-scale prospective study to investigate the efficacy of a GM-CSF-containing medium for frozen-thawed blastocyst transfer. The study findings will provide evidence regarding the efficiency of GM-CSF-containing medium for blastocyst recovery culture after warming. TRIAL REGISTRATION: Japan Registry of Clinical Trials jRCT1040240159. Registered on January 6, 2025.
-
Movement disorders : official journal of the Movement Disorder Society 2026年2月2日BACKGROUND: Alterations in tryptophan-kynurenine (TRP-KYN) metabolism, which is associated with neuroinflammation, remain unclear in multiple system atrophy (MSA). OBJECTIVE: The aim was to investigate cerebrospinal fluid (CSF) TRP metabolites in MSA and their associations with other biomarkers. METHODS: A total of 51 patients with MSA and 56 controls were included. CSF TRP metabolites, such as KYN, quinolinic acid (QA), and kynurenic acid (KA), along with neurofilament light chain (NfL), glycoprotein nonmetastatic melanoma protein B (GPNMB), and soluble triggering receptor expressed on myeloid cells 2 (sTREM2), were analyzed. RESULTS: Patients with MSA exhibited higher levels of QA, a neuroinflammatory marker, and lower levels of KA, a neuroprotective marker, yielding an elevated QA-to-KA ratio. Neither QA nor KA correlated with clinical scores. GPNMB, sTREM2, and NfL were increased; however, these markers were independent of KYN pathway metabolites. CONCLUSIONS: MSA exhibited a significant imbalance in KYN metabolism, suggesting a shift toward inflammatory processes distinct from classic neuroinflammatory markers. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
MISC
312-
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 331(1) 319-326 2009年10月 査読有り
-
日本アルコール・薬物医学会雑誌 = Japanese journal of alcohol studies & drug dependence 44(4) 332-333 2009年8月28日
-
BRITISH JOURNAL OF PHARMACOLOGY 157(7) 1270-1277 2009年8月 査読有り
-
日本臨床精神神経薬理学会・日本神経精神薬理学会合同年会プログラム・抄録集 19th-39th 2009年
-
JOURNAL OF PHARMACOLOGICAL SCIENCES 109 56P-56P 2009年
-
JOURNAL OF PHARMACOLOGICAL SCIENCES 109 224P-224P 2009年
-
JOURNAL OF PHARMACOLOGICAL SCIENCES 109 56P-56P 2009年
-
NEUROSCIENCE RESEARCH 65 S127-S127 2009年
-
JOURNAL OF PHARMACOLOGICAL SCIENCES 106 223P-223P 2008年
-
日本アルコール・薬物医学会雑誌 = Japanese journal of alcohol studies & drug dependence 42(4) 370-371 2007年8月28日
-
分子精神医学 7(2) 169-172 2007年4月アミロイドβペプチド(Aβ)の代謝酵素であるネプリライシンの活性を低下させることによって脳内Aβが蓄積し、これにより神経細胞の機能が障害されるとの仮説をたて、検証を行った。Aβ前駆体蛋白質トランスジェニックマウス(APP+)とネプリライシン欠損マウス(NEP-/-)を交配してAPP+×NEP-/-マウスを作製し、脳内Aβの蓄積、シナプス可塑性、学習機能などについて生化学的・行動学的手法を用いて検討した。結果、ネプリライシンの活性低下はシナプスとアクソンにおけるAβオリゴマーの増加を引き起こし、シナプス可塑性を低下させ、認知機能の障害をもたらすことが示唆された。
-
JOURNAL OF PHARMACOLOGICAL SCIENCES 103 237P-237P 2007年
-
JOURNAL OF PHARMACOLOGICAL SCIENCES 103 128P-128P 2007年
-
依存性薬物および未規制薬物による神経毒性と精神病の発現機序 平成18年度 総括研究報告書 平成16-18年度 総合研究報告書 199-207 2007年
-
依存性薬物および未規制薬物による神経毒性と精神病の発現機序 平成18年度 総括研究報告書 平成16-18年度 総合研究報告書 16-25 2007年
-
Japanese Journal of Molecular Psychiatry 7(2) 169-172 2007年
-
医学のあゆみ 217(13) 1155-1159 2006年6月24日
-
医学のあゆみ 217(13) 1155-1159 2006年6月
-
JOURNAL OF PHARMACOLOGICAL SCIENCES 100 147P-147P 2006年
-
JOURNAL OF PHARMACOLOGICAL SCIENCES 100 142P-142P 2006年
-
JOURNAL OF PHARMACOLOGICAL SCIENCES 100 96P-96P 2006年
-
依存性薬物および未規制薬物による神経毒性と精神病の発現機序 平成17年度 総括研究報告書 16-25 2006年
-
JOURNAL OF PHARMACOLOGICAL SCIENCES 97 100P-100P 2005年
-
JOURNAL OF PHARMACOLOGICAL SCIENCES 97 60P-60P 2005年
-
依存性薬物および未規制薬物による神経毒性と精神病の発現機序 平成16年度 総括研究報告書 13-20 2005年
-
精神薬療研究年報 (37) 144-150 2005年フェンシクリジン(PCP)連続投与後に認められる精神行動障害の発現機序を解明するため,PCP連続投与後におけるグルタミン酸作動性神経系の機能変化を分子生物学的に検討した.6〜7週齢のddY系雄性マウスを使用し,PCP動物モデルを作製した.PCP連続投与マウスに認められる精神行動障害には,グルタミン酸作動性神経系の前シナプス機能およびNMDA受容体を介する細胞内シグナル伝達の低下が関与していることが示唆された
書籍等出版物
1共同研究・競争的資金等の研究課題
16-
日本学術振興会 科学研究費助成事業 2025年4月 - 2028年3月
-
科学技術振興機構 戦略的な研究開発の推進 創発的研究支援事業 2022年 - 2028年
-
日本学術振興会 科学研究費助成事業 2022年4月 - 2025年3月
-
日本学術振興会 科学研究費助成事業 基盤研究(C) 2020年4月 - 2023年3月
-
日本学術振興会 科学研究費助成事業 基盤研究(B) 2017年4月 - 2022年3月
産業財産権
16メディア報道
5-
夕刊フジプレゼンツ 健活手帖ONLINE https://www.zakzak.co.jp/lif/news/210823/hea2108230001-n1.html 2021年8月 インターネットメディア
-
刑事事件弁護士ナビ 違法薬物で罰せられる薬物四法とは|依存症回復は可能? https://keiji-pro.com/magazine/175/ 2020年11月11日 インターネットメディア
-
ラジオNIKKEI 薬学の時間 http://medical.radionikkei.jp/yakugaku/tag/tag_953.html 2010年3月 テレビ・ラジオ番組